globenewswire.com
Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026
- Late breaking Poster Presentation at AAAAI -- Ability to retreat facilitates a real-world paradigm in which treatment for ColdU and SD may be intermittent with barzolvolimab - HAMPTON, N. J. , March 01, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ: CLDX) presented new positive data from the Phase 2 ColdU and SD Open Label Extension (OLE), highlighting that retreatment with barzolvolimab leads to rapid improvement in urticaria control after symptom recurrence.
